Fraunhofer Biotech-Enhanced Plant Growth to be Commercialized by Delaware Research Center
"We're very excited about this partnership," said Dr. Kewal K. Likhyani, a former director of Licensing & Joint-Ventures and Patent Fellow at DuPont / INVISTA and current president of IP2R. "Our initial focus will be on Fraunhofer's virus-induced gene silencing technology which significantly promotes high-yield plant growth. Commercializing or licensing the technology through collaborations will allow us to get to market much faster."
The Fraunhofer USA Center for Molecular Biotechnology (FhCMB) is a not-for-profit, contract research organization focused on developing and applying plant science and other core platform technologies for the production of valuable proteins.
"Our transient gene expression technology," said Barry Marrs, executive director of FhCMB, "allows us to provide exceptional protein yields in a very short time. Our hope is that by working in conjunction with IP2R, a firm dedicated to rapidly bringing inventions to market, we can take better advantage of what the technology has to offer."
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.